Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.
Consumer genetics testing service 23andMe has agreed to acquire US-based online healthcare provider Lemonaid Health in $400m deal which would provide exits for pharmaceutical firms Novartis and Hikma.
Founded in 2014, Lemonaid provides an online platform where users can virtually see physicians and get treatment and medication for a range of illnesses such as diabetes, high blood pressure or asthma, or access mental health services.
A quarter of the purchase price will be paid in cash while the remaining 75%…
